TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01044108
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a comparator at each dose level.
Study: NCT00195455
Drug: 17b Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01778634
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin intravenous 20 mg/kg every 24 h x 3 days
Study: NCT01778634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: D5W
Study: NCT00999817
Drug: test [PF-00299804 + dextromethorphan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
Study: NCT00959218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral solution
Study: NCT01117649
Drug: HES 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
Study: NCT01117649
Drug: HES 6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
Study: NCT01117649
Drug: balanced electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: plasma adapted Ringer's solution
Study: NCT00534456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
Study: NCT03302208
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02258867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT00444587
Drug: Second line chemotherapy
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT04407273
Drug: observational
Approvals — FDA: no, EMA: no, PMDA: no
Description: observational study
Study: NCT04170465
Drug: AC-T chemotherapy regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC: (Doxorubicin 60 mg/m2 IV + cyclophosphamide 600 mg/m2 IV) for 4 cycles every 3 weeks followed by Taxol cycles (Paclitaxel 80 mg/m2 IV) once weekly for 12 weeks.
Study: NCT00720421
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7325 10 mg oral 2 capsules
Study: NCT00720421
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7325 1 mg oral 2 capsules
Study: NCT00720421
Drug: AZD7325
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7325 Placebo oral 2 capsules
Study: NCT02670330
Drug: SD-101-6.0 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Study: NCT03359694
Drug: DT group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin 30mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
Study: NCT03359694
Drug: ET group
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doxorubicin 75mg/m2，iv，d1， Docetaxel 75mg/m2，iv，d1， q21d×6
Study: NCT03359694
Drug: NX group
Normalized name: Replesta NX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Navelbine IVD 25 mg/m2 D1、D8 Xeloda PO 1000 mg/m2 bid D1-D14 q21d
Study: NCT03452891
Drug: Simvastatin-Methylcellulose
Normalized name: Methylcellulose
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin-Methylcellulose gel will be placed in a deep (6-9 mm) periodontal pocket.
Study: NCT03005665
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02446405
Drug: NSAA
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00741338
Drug: Azathioprine (Aza)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally either every day for Cohort 1 or every other day for Cohort 2.
Study: NCT02446405
Drug: LHRHA or Surgical Castration
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01059578
Drug: GSK206136
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK206136 2mg, 10mg, 50mg, 100mg capsule
Study: NCT01059578
Drug: PLACEBO
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
Study: NCT00582660
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg twice a day for 7 days prior to surgery
Study: NCT00582660
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo will be given for 7 days prior to surgery
Study: NCT02255968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules. All interventions are given as multiple doses
Study: NCT02447601
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200µg,injected subcutaneously,once a week.
Study: NCT02447601
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg,oral,two times
Study: NCT01181570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
Study: NCT00659243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week treatment
Study: NCT01554319
Drug: SB010
Normalized name: CATH,EXTERN SURESTEP START KIT #MECSB010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.~Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL.
Study: NCT01554319
Drug: Placebo (phosphate-buffered saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).~Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
Study: NCT03277066
Drug: Diclofenac Sodium Active Topical Patch 1
Normalized name: diclofenac sodium Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-5000 Active Topical Patch 1 were applied on subjects with Osteoarthritis of the knee(s)
Study: NCT03277066
Drug: Diclofenac Sodium Active Topical Patch 2
Normalized name: diclofenac sodium Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: HP-5000 Active Topical Patch 2 were applied on subjects with Osteoarthritis of the knee(s)
Study: NCT03277066
Drug: Placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo patches were applied on subjects with Osteoarthritis of the knee(s)
Study: NCT00778388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
Study: NCT01794247
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02253004
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00511732
Drug: Technosphere Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technosphere Inhalation Powder
Study: NCT00188266
Drug: cisplatinum combined with infusional fluorouracil (5 FU)
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
Study: NCT01513278
Drug: APN201
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
Study: NCT01513278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.~Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size).
Study: NCT01799837
Drug: [C-11]MENET
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
Study: NCT03500380
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2000 mg/m\^2 orally daily on Days 1-14 of each 21-day treatment cycle.
Study: NCT00866944
Drug: FOLFOX 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX 4, every 14 days, 12 cycles
Study: NCT02934464
Drug: FOLFOX 4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02934464
Drug: mFOLFOX 6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02934464
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02914353
Drug: EP=7041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Factor X!a Inhibitor
Study: NCT02914353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline
Study: NCT01252277
Drug: Lovaza™
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules daily for 6 months
Study: NCT00030472
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02454855
Drug: melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line of anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).~Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg.
Study: NCT02454855
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line anticancer treatment (or no later on the day of the second administration of the new line of anticancer treatment).
Study: NCT00098774
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX \< or = 0.05uM Cycles 1-5.
Study: NCT00098774
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 g/sq m IV infusion over 4 hrs Days 1 \& 15 Cycles 1, 2, \& 3; Day 15 Cycle 4 and Day 1 Cycle 5.
Study: NCT00604682
Drug: CC10004
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
Study: NCT00285103
Drug: SPC2996
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01478399
Drug: PB1023 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg Dose
Study: NCT00780702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
Study: NCT02006732
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00321178
Drug: SR4 - switch to CR4
Approvals — FDA: no, EMA: no, PMDA: no
Description: switch to oral treatment after 4 weeks SR 'standard' therapy
Study: NCT00006123
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00690066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of excipients of PROCHYMAL®
Study: NCT00299130
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
Study: NCT00299130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to rituximab intravenous infusion
Study: NCT03732430
Drug: IBI308
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized anti-PD-1 monoclonal antibody
Study: NCT02171195
Drug: BIA 2-093
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
Study: NCT02171195
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo administered as oral tablets with 200 ml potable water.
Study: NCT03405922
Drug: Placebo 40 mL Saline 0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 40 mL 0.9% saline
Study: NCT01897805
Drug: Heart-protecting Musk Pill
Normalized name: Tri-Heart Plus Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01897805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02286258
Drug: Calcium EDTA
Normalized name: Calcium EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.~Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR
Study: NCT02965417
Drug: Sym004
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
Study: NCT02109653
Drug: LGX818
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral LGX818 300mg daily
Study: NCT01555697
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
Study: NCT03198676
Drug: PrEP-001 6.4 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
Study: NCT03198676
Drug: PrEP-001 3.2 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
Study: NCT01331993
Drug: Marketed enteric-coated naproxen formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
Study: NCT04604795
Drug: GSK3915393 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3915393 capsules will be given orally.
Study: NCT04604795
Drug: GSK3915393 Solution for Infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3915393 solution for infusion will be administered intravenously.
Study: NCT04604795
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching GSK3915393 capsules will be given orally.
Study: NCT00384553
Drug: TEC
Normalized name: Ultec
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01434914
Drug: octenisept®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous solution
Study: NCT01434914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cutaneous use
Study: NCT03278691
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15 mg (15 mg/ml) IV Q6H
Study: NCT02623296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
Study: NCT03875001
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each dose group a placebo group was given matching placebo tablets, participants were randomized within each dose group in a 3:1 ratio (active drug:placebo), tablets taken orally with \~240 milliliter of water 30 minutes after a standard high-fat, high-calorie meal (after an overnight fast of 10 hours).
Study: NCT02239679
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20% ALA applied to face for one hour prior to 10 J/cm2 blue light
Study: NCT02644473
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT02198963
Drug: 0.9% Physiological Saline, USP
Approvals — FDA: no, EMA: no, PMDA: no
Description: negative control
Study: NCT02300155
Drug: Pregvit®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
Study: NCT02300155
Drug: Orifer F®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
Study: NCT00695305
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02336646
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03324646
Drug: [11C]PS13
Approvals — FDA: no, EMA: no, PMDA: no
Description: A novel PET ligand to selectively image COX-1
Study: NCT01182376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by the patient's team according to established guidelines.
Study: NCT05327231
Drug: IN10018
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN10018 orally once daily at approximately the same time each day, to ensure a dose interval of approximately 24 hours.
Study: NCT01808573
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03181880
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brochodilators
Study: NCT00382057
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00822692
Drug: Trim/ Sulfa DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: bactrim DS (800/160) two tablets PO BID x 7 days
Study: NCT00822692
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched placebo 2 pills PO BID x 7 days
Study: NCT05927597
Drug: INS1007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets.
Study: NCT05927597
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets.
Study: NCT02797197
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03633097
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients after surgery receive usual care alone(Cnoxane Injection 40mg, Esomezol Capsule, Synerjet Semi Tablet and Ocoron Tablet)
Study: NCT01510782
Drug: Placebo to BI 655064
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of escalating doses
Study: NCT01510782
Drug: Placebo to BI 655064
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection of escalating doses
Study: NCT03953612
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01593046
Drug: GSK1265744 LAP 800mg intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg Loading dose given at month 1 dose
Study: NCT01593046
Drug: GSK1265744 LAP 200mg subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg maintenance dose give at months 2 - 4